<SEC-DOCUMENT>0001558370-20-008848.txt : 20200731
<SEC-HEADER>0001558370-20-008848.hdr.sgml : 20200731
<ACCEPTANCE-DATETIME>20200731090928
ACCESSION NUMBER:		0001558370-20-008848
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20200731
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200731
DATE AS OF CHANGE:		20200731

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GLYCOMIMETICS INC
		CENTRAL INDEX KEY:			0001253689
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36177
		FILM NUMBER:		201063912

	BUSINESS ADDRESS:	
		STREET 1:		9708 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		240-243-1201

	MAIL ADDRESS:	
		STREET 1:		9708 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>glyc-20200731x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7401.38943 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 7/31/2020 1:09:11 PM -->
      <!-- iXBRL Library version: 1.0.7401.38955 -->
      <!-- iXBRL Service Job ID: 78576bd6-2a43-4e02-b9de-22e7e35cb8d0 -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:glyc="http://www.glycomimetics.com/20200731" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg" name="dei:EntityCentralIndexKey" id="Tc_M3of8u4eB0GplTXoUfdi1w_2_1">0001253689</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg" name="dei:AmendmentFlag" id="Tc_VycMWL7PiU6nT0eWTwYPgw_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="glyc-20200731.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-31</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:9.41%;padding-right:9.41%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;border-top:9pt double #000000;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_6d4daa2f_d1c6_4998_b8ae_d08a6cab9af3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;letter-spacing:-0.1pt;line-height:1.19;text-align:center;margin:0pt;">UNITED STATES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;letter-spacing:-0.1pt;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">Washington, DC 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">FORM </b><ix:nonNumeric contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg" name="dei:DocumentType" id="Narr_gXnil4aI4kiMunD1simbMg"><b style="font-weight:bold;letter-spacing:-0.1pt;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">Pursuant to Section 13 or 15(d) of</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">The Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;letter-spacing:-0.1pt;">Date of Report (Date of earliest event reported):</b><b style="font-size:9pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_9bT9ST9jy0-4IIvM5Zgr0Q"><b style="font-size:9pt;font-weight:bold;">July 31, 2020</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg" name="dei:EntityRegistrantName" id="Narr_IwlnfSBYn0GsmNkeM3XthA"><b style="font-weight:bold;letter-spacing:-0.1pt;">GlycoMimetics, Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(Exact name of registrant as specified in its charter)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><a id="_e1f4de58_61bd_4709_b865_8049cd6378dd"></a><a id="Tc_F85tIZI24ESDEV1QcaPusg_2_0"></a><a id="Tc_j6SODR1oJkOy2Yi0wsabQg_2_2"></a><a id="Tc_CbQQaKD-JE-GDCjANDM5Zw_2_4"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:29.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:31.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:32.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:29.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_OdtZMV2dXUyXru3-RtTYSQ_1_0"><b style="font-size:9pt;font-weight:bold;letter-spacing:-0.1pt;text-decoration:underline;text-decoration-color:#000000;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:3.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg" name="dei:EntityFileNumber" id="Tc_NJV-mtoiVEmxTBzuUkGMzQ_1_2"><b style="font-size:9pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">001-36177</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg" name="dei:EntityTaxIdentificationNumber" id="Tc_vX5NWvMdpEGif57OGOfCCQ_1_4"><b style="font-size:9pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">06-1686563</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:29.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(State or other jurisdiction of</span> <span style="letter-spacing:-0.1pt;">incorporation)</span></p></td><td style="vertical-align:bottom;width:3.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(Commission File Number)</span></p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(IRS Employer</span><br /><span style="letter-spacing:-0.1pt;">Identification No.)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg" name="dei:EntityAddressAddressLine1" id="Narr_iQb3GzcDBUGlPmDJdSif7A"><b style="font-size:9pt;font-weight:bold;">9708 Medical Center Drive</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg" name="dei:EntityAddressCityOrTown" id="Narr_sQpy1Sklc0ORCOWV1fuO-w"><b style="font-size:9pt;font-weight:bold;">Rockville</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg" name="dei:EntityAddressStateOrProvince" id="Narr_62dtqiqsGEGSFQ5CoxkSxA"><b style="font-size:9pt;font-weight:bold;">MD</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg" name="dei:EntityAddressPostalZipCode" id="Narr_fNHnlhc160-HygyWaxJ7ig"><b style="font-size:9pt;font-weight:bold;">20850</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(Address of principal executive offices, including zip code)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg" name="dei:CityAreaCode" id="Narr_UNEV2yIz-keKvAsh7V25Kg"><b style="font-size:9pt;font-weight:bold;">240</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg" name="dei:LocalPhoneNumber" id="Narr_4thJLKaaBEyK0kk4VsEkgw"><b style="font-size:9pt;font-weight:bold;">243-1201</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(Registrant&#8217;s telephone number, including area code)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(Former name or former address, if changed since last report)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.25pt;text-indent:-14.25pt;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_u3VKrqy230WqHALV-JtmOQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;"> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.25pt;text-indent:-14.25pt;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_OxJEcHVynkuWKXhLqMP3-g"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-family:'Segoe UI Symbol';font-size:9pt;"> </span><span style="font-size:9pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.25pt;text-indent:-14.25pt;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_iZFGjoKXZEOyKhiAOjndcA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-family:'Segoe UI Symbol';font-size:9pt;"> </span><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.1pt;padding-left:14.25pt;text-indent:-14.25pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_S4cjl7LpuEGTPlnBotB07w"><span style="font-family:'Segoe UI Symbol';font-size:9pt;letter-spacing:0pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;letter-spacing:0pt;"> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.1pt;padding-left:14.25pt;text-indent:-14.25pt;margin:0pt;"><span style="font-size:9pt;letter-spacing:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><a id="_815aaab8_f3ad_460f_b7c2_43bd0f552b4c"></a><div style="margin-left:0pt;"><a id="Tc_SBNZTwL2HUS9o0rhMDj5mQ_1_0"></a><a id="Tc_qcoScrsZuUSf4-29JeQmeQ_1_1"></a><a id="Tc_7pNkZBOaiU6zL59KQMfjnw_1_2"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;width:97.58%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:22.29%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:44.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.34%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:5pt 0pt 5pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Title of each class</b></p></td><td style="vertical-align:top;width:22.29%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:5pt 0pt 5pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:44.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:5pt 0pt 5pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:33.34%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg" name="dei:Security12bTitle" id="Tc__vhyndgotEyeS_FzD74Fcg_2_0"><span style="font-size:9pt;">Common Stock, $0.001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:22.29%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg" name="dei:TradingSymbol" id="Tc_fIswYx8liEWWUByYW_lcqQ_2_1"><span style="font-size:9pt;">GLYC</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:44.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_okZhIJgaRUOxSFJf9I3xkg_2_2"><span style="font-size:9pt;">The Nasdaq Stock Market</span></ix:nonNumeric></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Ind&#237;cate by check mark whether the registrant is an emerging growth Company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.1pt;padding-left:14.25pt;text-indent:-14.25pt;margin:0pt;"><span style="font-size:9pt;letter-spacing:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;">Emerging Growth Company </span><ix:nonNumeric contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_t5u7CzGKPEWnaC9c7gyODg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;width:97.58%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> <span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:22.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:44.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:22.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:44.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;border-bottom:9pt double #000000;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Courier New';line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_bd162b92_947c_412a_86b2_db6bb91beb9f"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:81.18%;border:0;margin:30pt 9.41% 30pt 9.41%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Item 2.02 &#160;Results of Operations and Financial Condition.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On July 31, 2020, GlycoMimetics, Inc. (the &#8220;<span style="font-style:italic;font-weight:bold;">Registrant</span>&#8221;) issued a press release announcing its financial results for the second quarter ended June 30, 2020. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;<span style="font-style:italic;font-weight:bold;">Exchange Act</span>&#8221;), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant&#8217;s filings under the Securities Act of 1933, as amended, or the Exchange Act, <span style="font-family:'inherit';">whether made before or after the date hereof, </span>regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Item 9.01 Financial Statements and Exhibits. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(d)&#160;Exhibits</b></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:10.27%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:88.13%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:10.27%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.13%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.13%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;Description</b></p></td></tr><tr><td style="vertical-align:top;width:10.27%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">99.1</p></td><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.13%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="glyc-20200731xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Press Release, dated July 31, 2020, &#8220;GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2020&#8221;</span></a> </p></td></tr><tr style="height:4.3pt;"><td style="vertical-align:top;width:10.27%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><div style="height:4.3pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"><div style="height:4.3pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:88.13%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><div style="height:4.3pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:10.27%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.13%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0.05pt;margin:0pt;"><span style="font-size:0.05pt;visibility:hidden;">&#8203;</span></p><a id="_4042cad7_46ec_49d0_9f15_0b21290e2db9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;letter-spacing:-0.1pt;line-height:1.19;text-align:center;margin:0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.1pt;text-align:justify;text-indent:37.05pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0.7pt;padding-right:0.7pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></div></div></td><td style="vertical-align:top;width:20.14%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.14%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">GLYCOMIMETICS, INC.</p></td></tr><tr><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.14%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.14%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="letter-spacing:-0.1pt;">By:&#160;&#160;</span></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;">/s/ </span>Brian M. Hahn</p></td></tr><tr><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:-0.1pt;white-space:pre-wrap;">Date:  </span>July 31, 2020</p></td><td style="vertical-align:top;width:20.14%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Brian M. Hahn<br />Chief Financial Officer and Senior Vice President</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>glyc-20200731xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.7.0.58--><!--Created on: 7/31/2020 01:09:05 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 99.1</b></p><p style="font-family:'Courier New';font-size:12pt;font-weight:bold;line-height:1.19;text-align:justify;text-transform:uppercase;margin:0pt 41.75pt 0pt 0pt;"><img src="glyc-20200731xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:58.4pt;width:271pt;"></p><p style="font-family:'Courier New';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-transform:uppercase;margin:0pt 41.75pt 0pt 41.75pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';text-transform:none;visibility:hidden;margin:24pt 0pt 18pt 0pt;">&#8203;</font></p><p style="font-family:'Courier New';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-transform:uppercase;margin:0pt 41.75pt 0pt 41.75pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;text-transform:none;visibility:hidden;margin:24pt 0pt 18pt 0pt;">&#8203;</font></p><p style="font-family:'Courier New';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-transform:uppercase;margin:0pt 41.75pt 0pt 36pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;text-transform:none;visibility:hidden;margin:24pt 0pt 18pt 0pt;">&#8203;</font></p><p style="font-family:'Courier New';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-transform:uppercase;margin:0pt 41.75pt 0pt 36pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;text-transform:none;visibility:hidden;margin:24pt 0pt 18pt 0pt;">&#8203;</font></p><p style="font-family:'Courier New';font-size:11pt;font-weight:bold;line-height:1.19;text-align:center;text-transform:uppercase;margin:0pt 41.75pt 0pt 36pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;text-transform:none;">G</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;text-transform:none;">LYCOMIMETICS </b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;text-transform:none;">REPORTS HIGHLIGHTS AND FINANCIAL RESULTS FOR </b></p><p style="font-family:'Courier New';font-size:11pt;font-weight:bold;line-height:1.19;text-align:center;text-transform:uppercase;margin:0pt 41.75pt 0pt 36pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;text-transform:none;">SECOND QUARTER 2020</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 21pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:0pt 0pt 21pt 0pt;"><i style="color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:normal;line-height:1.19;text-align:left;">Enrollment in the Company-sponsored pivotal Phase 3 trial evaluating uproleselan in patients with relapsed/refractory acute myeloid leukemia (AML) continued, and the company affirmed second half of 2021 as target for completion of enrollment</i></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 21pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:0pt 0pt 21pt 0pt;"><i style="color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:normal;line-height:1.19;text-align:left;">A&#160;post hoc&#160;analysis of the Phase 3 RESET study evaluating the efficacy of rivipansel in acute vaso-occlusive crisis (VOC) in sickle cell disease (SCD) produced new efficacy data showing statistically significant improvements for patients treated early in crisis in the primary efficacy endpoint of time to readiness for discharge compared to placebo</i></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="background-color:#ffffff;padding:0pt;"><i style="color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:normal;line-height:1.19;text-align:left;">Pfizer completed the transfer to GlycoMimetics of all commercial and development rights and the Investigational New Drug Application (IND) for rivipansel </i></td></tr></table><div style="margin-top:21pt;"></div><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 6pt 36pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;margin-bottom:5pt;margin-left:0pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-bottom:21pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">ROCKVILLE, MD</font><font style="font-family:'Calibri','Helvetica','sans-serif';">, July 31, 2020 --&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">GlycoMimetics, Inc.</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;(Nasdaq: GLYC) today reported its financial results for the second quarter ended&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">June 30, 2020</font><font style="font-family:'Calibri','Helvetica','sans-serif';">,&#160;and highlighted recent company events. Cash and cash equivalents at&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">June 30, 2020</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;were&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">$149.8 million</font><font style="font-family:'Calibri','Helvetica','sans-serif';">.</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-bottom:21pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">&#8220;The second quarter was quite productive as we noted strong enrollment in our company-sponsored pivotal trial of uproleselan in relapsed/refractory AML. Though we did see a slow down early in the COVID crisis, we were pleased to see enrollment pick back up later in the quarter. This was an important achievement in the face of the COVID-19 pandemic, and we are able to maintain prior guidance that we expect to complete enrollment in the second half of 2021. Also important were new data from a </font><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">post hoc </i><font style="font-family:'Calibri','Helvetica','sans-serif';">analysis of the rivipansel Phase 3 study that </font><font style="font-family:'Calibri','Helvetica','sans-serif';">showed that patients treated with rivipansel within approximately 26 hours of the onset of pain in their crisis experienced statistically significant improvements in the primary efficacy endpoint of time to readiness for discharge compared to placebo.&#160;These data provide a foundation, we believe, for us to discuss with the U.S. Food and Drug Administration (FDA) whether there may be a path forward for rivipansel in acute VOC,&#8221; commented</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">Rachel King</font><font style="font-family:'Calibri','Helvetica','sans-serif';">, Chief Executive Officer.</font></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:21pt;margin:0pt;"><font style="font-weight:bold;line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:21pt;margin:0pt;"><font style="font-weight:bold;line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 21pt 0pt;"><b style="font-weight:bold;">Operational Highlights</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="background-color:#ffffff;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Uproleselan</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">GlycoMimetics&#8217; ongoing pivotal Phase 3 trial in relapsed/refractory AML continued to activate clinical sites and enroll patients in North America,&#160;Australia&#160;and&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;white-space:pre-wrap;">Europe.  While individual sites were affected by COVID-19, overall clinicians continued to enroll patients well this quarter. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">At the </font><font style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">American Association for Cancer Research&#160;(AACR) Annual Meeting 2020</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">, held June 22-24, preclinical research for both uproleselan and GMI-1359 was shared in a virtual format. Preclinical data supporting the potential use of uproleselan in the treatment&#160;of AML as well as in the setting of stem cell transplantation were presented. Additionally, new information demonstrated the ability of transcriptome profiling to identify those tumor types most likely to benefit from targeted E-selectin inhibition, a key mechanism of&#160;GlycoMimetics&#160;drug candidates. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">Important new preclinical data on the mechanism of action for uproleselan were published in the&#160;April 27, 2020, issue of&#160;</font><i style="background-color:#ffffff;color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:normal;line-height:1.27;text-align:left;">Nature Communications.</i><font style="background-color:#ffffff;color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">&#160;The paper outlined how uproleselan, a first-in-class, targeted inhibitor of E-selectin, can reduce chemoresistance in AML through the key mechanism of targeted E-selectin inhibition.</font></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="background-color:#ffffff;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">GMI-1687</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">An abstract that was accepted for oral presentation at the Foundation for Sickle Cell Disease (FSCDR) meeting and published online in June, disclosed data from a preclinical model of the Company&#8217;s E-selectin antagonist, GMI-1687, which is more potent than rivipansel and is being formulated for subcutaneous dosing. The data support development of GMI-1687 as a possible follow-on to rivipansel, which has the potential for subcutaneous self-administration as would be used in an outpatient setting. </font></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="background-color:#ffffff;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Rivipansel</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">The FSCDR also published online an abstract including data from a </font><i style="background-color:#ffffff;color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:normal;line-height:1.27;text-align:left;">post hoc</i><font style="background-color:#ffffff;color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;"> analysis of the Phase 3 RESET trial of 345 patients (ranging in age from six years to adults, with a mean age of 22 years) who were experiencing acute VOC requiring hospitalization for treatment. The organization selected the abstract for poster presentation at its September meeting. The analysis showed that patients treated with rivipansel early in their acute episode experienced a statistically significant improvement on the primary efficacy endpoint, time to readiness for discharge (p=0.03, median improvement at 56.3 hours compared to placebo).&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">Based upon its review of the Phase 3 rivipansel data set, GlycoMimetics is committed to an assessment of what, if any, next steps to take, with a focus on determining if there is a potential path forward for this asset in sickle cell disease. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">GlycoMimetics completed in April a transfer back from Pfizer of the commercial and development rights and licenses for rivipansel, the IND for the clinical development program, and the entire data set for the Phase 3 RESET trial.</font></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin:0pt;"><font style="background-color:#ffffff;line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin:0pt;"><font style="background-color:#ffffff;line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin:0pt;"><font style="background-color:#ffffff;line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin:0pt;"><font style="background-color:#ffffff;line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="background-color:#ffffff;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Executive Management Team</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">The Company announced that veteran regulatory expert&#160;Myra Rosario Herrle, PhD, RPh, RAC, joined the executive management team as Vice President, Regulatory Affairs.</font></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.79;margin:14pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Second Quarter 2020 Financial Results:</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.26;margin-bottom:0pt;margin-top:14pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.26;text-align:left;white-space:pre-wrap;">Cash position: As of June 30, 2020, GlycoMimetics had cash and cash equivalents of $149.8 million as compared to $158.2 million as of December 31, 2019.  During the quarter, the Company sold common stock under its at-the-market facility with Cowen for aggregate net proceeds of $9.6 million.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 22.3pt;"><font style="line-height:1.37;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.26;text-align:left;">R&amp;D Expenses: The Company&#8217;s research and development expenses decreased to $9.9 million for the quarter ended June 30, 2020 as compared to $13.1 million for the second quarter of 2019. The Company&#8217;s research and development expenses decreased to $22.5 million for the six months ended June 30, 2020 as compared to $24.8 million for the same period in 2019. These decreases were due primarily to a decrease in manufacturing and formulation expenses resulting from lower raw material costs as the validation manufacturing batches were purchased in the prior year. The decreases were offset in part by higher clinical expenses as a result of the increased enrollment in the ongoing global Phase 3 clinical trial of uproleselan in individuals with relapsed/refractory AML and the Phase 2/3 clinical trial being conducted by the National Cancer Institute. Contract research services, consulting and other costs were lower in 2020 as research activities were affected at outside universities and travel by research and development personnel was largely eliminated due to the COVID-19 pandemic.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 22.3pt;"><font style="line-height:1.37;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;white-space:pre-wrap;">G&amp;A Expenses: The Company&#8217;s general and administrative expenses increased to $4.2 million for the second quarter ended June 30, 2020 as compared to $3.8 million for the second quarter of 2019.  General and administrative expenses for the six months ended June 30, 2020 increased to $8.7 million as compared to $7.1 million in the same period in 2019.  </font><font style="color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;white-space:pre-wrap;">Personnel-related expenses increased due to additional general and administrative headcount, annual salary adjustments awarded in the first quarter of 2020 and retention bonuses. Patent, legal fees, consulting and other professional expenses including director and officer&#8217;s insurance premiums, increased as compared to 2019.  Other general and administrative expenses decreased for both the three and six months ended June 30, 2020, as compared to the same periods in 2019, due to lower travel, meals and conference registration expenses as a result of the travel restrictions due to the COVID-19 pandemic.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 22.3pt;"><font style="line-height:1.37;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;white-space:pre-wrap;">Shares Outstanding:  Shares of common stock outstanding as of June 30, 2020 were 46,714,698.</font></td></tr></table><div style="margin-top:8pt;"></div><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-bottom:21pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">The Company will host a conference call and webcast today at&#160;8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 for domestic participants or (216) 562-0466 for international participants, with participant code 1677593. Participants are encouraged to connect 15 minutes in advance of the call to ensure that all callers are able to connect. A webcast replay will be available via the &#8220;Investors&#8221; tab on the&#160;GlycoMimetics&#160;website for 30 days following the call. A dial-in phone replay will be available for 24 hours after the close of the call by dialing (855)-859-2056 for domestic participants and (404) 537-3406</font><font style="color:#1f3864;font-size:12pt;"> </font><font style="font-family:'Calibri','Helvetica','sans-serif';">for international participants, participant code 1677593.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.79;padding-bottom:12pt;margin:0pt;"><b style="font-weight:bold;">About Uproleselan (GMI-1271)</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-bottom:21pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Discovered and developed by&#160;GlycoMimetics, uproleselan and GMI-1687 are investigational, first-in-class, targeted inhibitors of E-selectin. Uproleselan (yoo&#8217; pro le&#8217; sel an), currently in a comprehensive Phase 3 development program in AML, has received Breakthrough Therapy Designation from the&#160;U.S.&#160;FDA for the treatment of adult AML patients with relapsed or refractory disease. Uproleselan is designed to block E-selectin (an adhesion molecule on cells in the bone marrow) from binding with blood cancer cells as a targeted approach to disrupting well-established mechanisms of leukemic cell resistance within the bone marrow microenvironment. In a Phase 1/2 clinical trial, uproleselan was evaluated in both newly diagnosed elderly and relapsed or refractory patients with AML. In both populations, patients treated with uproleselan together with standard chemotherapy achieved better-than-expected remission rates and overall survival compared to historical controls, which have been derived from results from third-party clinical trials evaluating standard chemotherapy, as well as lower-than-expected induction-related mortality rates. Treatment in these patient populations was generally well-tolerated, with fewer than expected adverse effects.</font></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.79;padding-bottom:12pt;margin:0pt;"><b style="font-weight:bold;">About GMI-1687</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-bottom:21pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">GMI-1687 is a rationally designed, innovative antagonist of E-selectin that is potentially suitable for subcutaneous (SC) administration. When given by SC injection in preclinical models, GMI-1687 has been observed to have equivalent activity to uproleselan, but at an approximately 1,000-fold lower dose.&#160;GlycoMimetics&#160;believes that GMI-1687 could be developed as a potential life-cycle expansion to broaden the clinical usefulness of an E-selectin antagonist to conditions, such as sickle cell disease crisis, where outpatient treatment may be preferred or required. GMI-1687 is currently undergoing IND-enabling studies.</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-bottom:21pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">About Rivipansel</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-bottom:21pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Rivipansel, a glycomimetic drug candidate that binds to all three members of the selectin family (E-, P- and L-selectin), was GlycoMimetics&#8217; first drug candidate to enter clinical development. After the Phase 3 RESET trial conducted by Pfizer, GlycoMimetics&#8217; former collaborator, did not meet its primary or key secondary efficacy endpoints in 2019, new efficacy data from a&#160;</font><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">post hoc</i><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;analysis of rivipansel were published in&#160;June 2020&#160;in advance of a presentation to occur at the&#160;Foundation for Sickle Cell Disease Research Meeting&#160;in&#160;September 2020.&#160;GlycoMimetics&#160;is committed to exploring a path forward for the use of rivipansel in treating acute VOC in SCD.</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-bottom:21pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">About GMI-1359</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">GMI-1359 is designed to simultaneously inhibit both E-selectin and CXCR4. E-selectin and CXCR4 are both adhesion molecules involved in tumor trafficking and metastatic spread. Preclinical studies indicate that targeting both E-selectin and CXCR4 with a single compound could improve efficacy in the treatment of cancers that involve the bone marrow such as AML and multiple myeloma or in solid tumors that metastasize to the bone, such as prostate cancer and breast cancer, as well as in osteosarcoma, a rare pediatric tumor. GMI-1359 has completed a Phase 1 clinical trial in healthy volunteers. The Duke University Phase 1b clinical study in breast cancer patients is designed to enable investigators to identify an effective </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-bottom:21pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">dose of the drug candidate and to generate initial biomarker data around the drug&#8217;s activity. GMI-1359 has received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA for the treatment of osteosarcoma, a rare cancer affecting about 900 adolescents a year in&#160;the United States.</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-bottom:21pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">About&#160;GlycoMimetics, Inc.</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-bottom:21pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">GlycoMimetics&#160;is a biotechnology company with two late-stage clinical development programs and a pipeline of novel glycomimetic drugs, all designed to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role.&#160;GlycoMimetics&#39;&#160;drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is being evaluated across a range of patient populations including a Company-sponsored Phase 3 trial in relapsed/refractory AML under breakthrough therapy designation. Rivipansel, a pan-selectin antagonist, is being explored as a potential treatment for acute VOC in SCD.&#160;GlycoMimetics&#160;has also completed a Phase 1 clinical trial with another wholly-owned drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist.&#160;GlycoMimetics&#160;is located in&#160;Rockville, MD&#160;in the&#160;BioHealth Capital Region. Learn more at&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">www.glycomimetics.com</font><font style="font-family:'Calibri','Helvetica','sans-serif';">.</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-bottom:21pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Forward-Looking Statements</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 21pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">This press release contains forward-looking statements regarding the Company&#8217;s strategy and the clinical development and potential utility, benefits and impact of its drug candidates. These forward-looking statements include those relating to the planned preclinical research and clinical development of the Company&#8217;s product candidates, including expectations with regard to the enrollment of patients in its ongoing Phase 3 clinical trial of uproleselan and the potential impact of the ongoing global COVID-19 pandemic on the Company&#8217;s operations, and the Company&#8217;s plans for discussing data from the Phase 3 clinical trial of rivipansel with the FDA. Actual results may differ materially from those expressed in or implied by these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing&#160;GlycoMimetics, please see the risk factors described in the Company&#8217;s annual report on Form 10-K filed with the&#160;U.S. Securities and Exchange Commission&#160;(SEC) on&#160;February 28, 2020, the updated risk factors described in the Company&#8217;s quarterly report on Form 10-Q filed with the&#160;SEC&#160;on&#160;July 31, 2020, and other filings&#160;GlycoMimetics&#160;makes with the&#160;SEC&#160;from time to time. Forward-looking statements speak only as of the date of this release, and&#160;GlycoMimetics&#160;undertakes no obligation to update or revise these statements, except as may be required by law.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.79;padding-top:3pt;margin:0pt 0pt 12pt 0pt;">Source:&#160;GlycoMimetics, Inc.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">GlycoMimetics Contacts </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;">Investor Contact:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">Shari Annes</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">Phone: 650-888-0902</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">Email: sannes@annesassociates.com</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;">Media Contact:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">Jamie Lacey-Moreira</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">Phone: 410-299-3310</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">Email: jamielacey@presscommpr.com</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:12pt;line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:12pt;">GlycoMimetics, Inc.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:12pt;">Condensed Statements of Operations</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:12pt;">(In thousands, except share and per share data)</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:12pt;line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Courier New';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-transform:uppercase;margin:0pt 41.75pt 0pt 41.75pt;"><font style="visibility:hidden;margin:24pt 0pt 18pt 0pt;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:43.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three months ended June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Revenue</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 9,000</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:43.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Costs and expenses:</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:43.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 18pt;">Research and development expense</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 18pt;"><font style="font-size:10pt;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 9,871</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 13,065</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 22,539</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 24,838</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 18pt;">General and administrative expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 18pt;"><font style="font-size:10pt;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 4,235</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 3,751</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 8,675</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 7,111</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:43.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 30pt;">Total costs and expenses</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 30pt;"><font style="font-size:10pt;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 14,106</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 16,816</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 31,214</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 31,949</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:43.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (14,106)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (16,816)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (22,214)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (31,949)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:43.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Interest income </p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 27</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 986</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 472</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 2,035</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:43.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Net loss and comprehensive loss</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (14,079)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (15,830)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (21,742)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (29,914)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:43.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Net loss per common share &#8211; basic and diluted</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (0.32)</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (0.37)</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (0.50)</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (0.69)</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:43.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Weighted-average common shares &#8211; basic and diluted</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 43,801,251</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 43,183,010</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 43,688,420</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 43,174,989</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:12pt;">GlycoMimetics, Inc.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:12pt;">Balance Sheet Data</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:12pt;">(In thousands)</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:67.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><font style="font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 149,845</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 158,201</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Working capital</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 143,657</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 151,577</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Total assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 158,353</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 167,970</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Total liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 12,600</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 13,769</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Total stockholders&#39; equity</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 145,752</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 154,201</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>glyc-20200731xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 glyc-20200731xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !U AX# 2(  A$! Q$!_\0
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M1W&:6BBO./3"L;Q9_P BIJ7_ %Q-;-8WBS_D5-2_ZXF@#AO@/_R)-W_U_/\
MR6J4_P 8;C2_%>I6&H6T36MLS)"L2GS'8$X%7?@/_P B3=_]?S_R6N0\/:+!
MK/QROA<H'B@DDEVG^\#D4 = /$'Q/UN,WVG:5#;VF=T:,<,P]\FM;P/\2;K5
MM9?0/$%H+35$SMP,*^.M>E !0 !@#@"O&?B-!]@^*.@ZA  DDI6-B.,\G/\
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MG\*[$# P*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
G"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>glyc-20200731.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7401.38943 -->
<!--Based on XBRL 2.1-->
<!--Created on: 7/31/2020 1:09:14 PM-->
<!--Modified on: 7/31/2020 1:09:14 PM-->
<xsd:schema targetNamespace="http://www.glycomimetics.com/20200731" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:glyc="http://www.glycomimetics.com/20200731">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="glyc-20200731_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="glyc-20200731_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="glyc_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>glyc-20200731_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7401.38943 -->
<!--Based on XBRL 2.1-->
<!--Created on: 7/31/2020 1:09:14 PM-->
<!--Modified on: 7/31/2020 1:09:14 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="glyc-20200731.xsd#glyc_DocumentAndEntityInformationAbstract" xlink:label="glyc_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="glyc_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>glyc-20200731_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7401.38943 -->
<!--Based on XBRL 2.1-->
<!--Created on: 7/31/2020 1:09:14 PM-->
<!--Modified on: 7/31/2020 1:09:14 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="glyc-20200731.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="glyc-20200731.xsd#glyc_DocumentAndEntityInformationAbstract" xlink:label="glyc_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637317977547914147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_637317977547914147" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637317977547914147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_637317977547914147" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637317977547914147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFileNumber_637317977547914147" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637317977547914147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_637317977547914147" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637317977547914147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637317977547914147" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637317977547914147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637317977547914147" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637317977547914147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine1_637317977547914147" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637317977547914147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCityOrTown_637317977547914147" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637317977547914147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressStateOrProvince_637317977547914147" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637317977547924107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressPostalZipCode_637317977547924107" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637317977547924107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_CityAreaCode_637317977547924107" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637317977547924107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_LocalPhoneNumber_637317977547924107" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_637317977547924107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_WrittenCommunications_637317977547924107" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_637317977547924107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_SolicitingMaterial_637317977547924107" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_637317977547924107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementTenderOffer_637317977547924107" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_637317977547924107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_637317977547924107" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637317977547924107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_Security12bTitle_637317977547924107" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637317977547924107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol_637317977547924107" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637317977547934126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_SecurityExchangeName_637317977547934126" order="19" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637317977547934126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637317977547934126" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637317977547934126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_637317977547934126" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637317977547934126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_637317977547934126" order="22" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>glyc-20200731x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="glyc-20200731.xsd" xlink:type="simple"/>
    <context id="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
        </entity>
        <period>
            <startDate>2020-07-31</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg"
      id="Tc_M3of8u4eB0GplTXoUfdi1w_2_1">0001253689</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg"
      id="Tc_VycMWL7PiU6nT0eWTwYPgw_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg"
      id="Narr_gXnil4aI4kiMunD1simbMg">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg"
      id="Narr_9bT9ST9jy0-4IIvM5Zgr0Q">2020-07-31</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg"
      id="Narr_IwlnfSBYn0GsmNkeM3XthA">GlycoMimetics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg"
      id="Tc_OdtZMV2dXUyXru3-RtTYSQ_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg"
      id="Tc_NJV-mtoiVEmxTBzuUkGMzQ_1_2">001-36177</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg"
      id="Tc_vX5NWvMdpEGif57OGOfCCQ_1_4">06-1686563</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg"
      id="Narr_iQb3GzcDBUGlPmDJdSif7A">9708 Medical Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg"
      id="Narr_sQpy1Sklc0ORCOWV1fuO-w">Rockville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg"
      id="Narr_62dtqiqsGEGSFQ5CoxkSxA">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg"
      id="Narr_fNHnlhc160-HygyWaxJ7ig">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg"
      id="Narr_UNEV2yIz-keKvAsh7V25Kg">240</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg"
      id="Narr_4thJLKaaBEyK0kk4VsEkgw">243-1201</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg"
      id="Narr_u3VKrqy230WqHALV-JtmOQ">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg"
      id="Narr_OxJEcHVynkuWKXhLqMP3-g">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg"
      id="Narr_iZFGjoKXZEOyKhiAOjndcA">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg"
      id="Narr_S4cjl7LpuEGTPlnBotB07w">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg"
      id="Tc__vhyndgotEyeS_FzD74Fcg_2_0">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg"
      id="Tc_fIswYx8liEWWUByYW_lcqQ_2_1">GLYC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg"
      id="Tc_okZhIJgaRUOxSFJf9I3xkg_2_2">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg"
      id="Narr_t5u7CzGKPEWnaC9c7gyODg">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139964492231880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 31,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GlycoMimetics, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1686563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9708 Medical Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">243-1201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GLYC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001253689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M"]>H$AD7G]PBA/V"L'\.X0M[)],(:DXL1;C[KDYG%U?TN\V@V^]VNBT$[ZK
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M7>EYIK=WDWM)J'7N0;#W\!J-'<V/'[?\ 5!+ P04    "  M2?]0)!Z;HJT
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M2P$"% ,4    "  M2?]0!T%-8H$   "Q    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( "U)_U "*06D[P   "L"   1
M              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M "U)_U"97)PC$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ +4G_4-0+;N(T!   8!   !@
M     ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M "U)_U"#J:4#U $  #(&   -              "  7@,  !X;"]S='EL97,N
M>&UL4$L! A0#%     @ +4G_4)>*NQS     $P(   L              ( !
M=PX  %]R96QS+RYR96QS4$L! A0#%     @ +4G_4!PX9>H_ 0  / (   \
M             ( !8 \  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( "U)
M_U D'INBK0   /@!   :              "  <P0  !X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( "U)_U!ED'F2&0$  ,\#   3
M          "  ;$1  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D
*/@(  /L2      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="glyc-20200731x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="glyc-20200731x8k.htm">glyc-20200731x8k.htm</File>
    <File>glyc-20200731.xsd</File>
    <File>glyc-20200731_lab.xml</File>
    <File>glyc-20200731_pre.xml</File>
    <File>glyc-20200731xex99d1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "glyc-20200731x8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "glyc-20200731x8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "glyc-20200731_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "glyc-20200731_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "glyc-20200731.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "glyc",
   "nsuri": "http://www.glycomimetics.com/20200731",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20200731x8k.htm",
      "contextRef": "Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20200731x8k.htm",
      "contextRef": "Duration_7_31_2020_To_7_31_2020_8B6mYKgpsUmu_jdKII3cxg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "glyc_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.glycomimetics.com/20200731",
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001558370-20-008848-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-20-008848-xbrl.zip
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MS$;#.MW/1CW#=GN=;N_LT;-=,=0[GIHDZI&:_._L9;BION*XISR"A^T<W7A
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MZ9NEL^(JF3,M50)=A*5I\W'%5:"0,:#;<"ZYTU)55U\NTZJ-F9\Y,Q!(M&%
MQ[-*9Z2Z@*5,('VZ0,TIH>>OT5V1,+@4@3:1,VE695;U)JLRJ:N[T[RO+%ZS
M68K\9[#NALH$NF-T;)QH1J]Z=2?:1=*,Q?-@UG;B8KA'8T)&.H?HVL<L3^DW
MT/DRGZ<!!;B'-.""_,:"P 6#Y-OHTB(WWT;PY_S"(G\*&725>E"*\N,9RD>
M\NB*_P_H7)C3$\H,%WAX]LKSP8#R("RA;M1-,][K29^W(GZRP#8.WM^JLKA_
MZT)&6>K\(:T.OE'5P:=;P@LZJWD!PL8P@_(Q@\YC\Y)E]78JI<FY=-3F:JWG
M'1LCJDN]"VN^X>E\"30R@*S#[V_U]DFUD?T5'KEDMG*-JMX ]5Z5D,LX2/+]
M=!ZSE8UWDA"H31I]Z)"-!!;2HH267AL*FS]B%4#4[VB4 >W(_#OI4+D0$Z9<
MO'0X!.Z'6>P>D[:=S9BCEM"K=I(IKN!-&V$\BZ4VLMRF46TNXM]C%.'YYA:E
M:'>W8;9D5)0MX4H'[V]^IF/_[))<@?*!CIE3<E>0U) F%\^[=IA^#"YB+W==
M:P_TVTM93.*3R37@R/.X12;5K-87!ICK4"!+WI%5K6/"0-_MQ1?R'P386S0*
M'S7I1BO#=M,Q*.89PQ8*Z4Y+9XS5UGH&NOK$B9/X#U=IQC2] Y\$_(Z!DT:*
M+>.RDK00?%VZ+-7]1&:-H(_.!6X;D(!."-:IRW"?+4)DT2JQ ^0&U]DS^1?T
M:62/DJGY,8"2AFG:IFY;@($^G7F27XH8#+3#&Z 383D--C+!ADV)5R^=KTQ'
M49-./(G<2W9FL>=!4CXU=$4_4SV5CKNLQ<2LX&=%GT69H:X]BVKDQO'"V"HE
M!S$Q3FJ%\/XO29&E+DNX]L*(1W'$JH";GHI0ID@))'T/2GEHX3C)?N&;A2R*
M5SLD(:GV3R*.PK@98F,)&*@-"\5+8%P RT5E'R0RF 1!J.Z2*PLHD +.>2F!
M *Z&PO.PSP&\SL78(J C<_D8=&@<'_$48R1%S2Z,L"ZAL#;^A!7"^JUE\J,K
M&#]*07W^@* >,@^K%2559Y/R[MF,Y<[X*TJM5L8:6-4RZP'AURR2?4L$-OGX
MB%D^4@CG%W-2[2XU?+H9E2(I/BH2SH5%<EN#)M\2]EV1+E\4HHO[KEDX3<NH
M5N$-GE9C@S8;8=A-EM6%U,4D%>K@D2>J.PW%@/=,/Y!9__F-1YSQL(N9#)7#
M'O2%%X=8Y?2-1M(OY8(QZ)(!6RH7L5R+A:&:<7992?89#QA*<O6(:H^24@:'
M 0-910#0&O-X#&^9060.630F?)6O?0Q-S;3)M/Q.5L&- FQ:!0^N1F-K?@)S
MV!DFZ&DE>Z<4 R7/,><'%1OI$1#> -0!7"<8U[.4W%4*E]8*X"*H.+)Z)S12
MWDAY(^5?GWW?8EEN2+Z" A]A(2@LAQ!]$:@UYV\3LYNT'R\O&J59T.I8W7K+
MZO1.UN3DWXW&A]G(S 1/FQMAOB_-LD],V-2]^_HV#2/==33IJGERV@2)5AU7
MR=6=-H+!/*P G_9BZ4M-,UGFAL3>X2>MUA%IU9N5;KW=4HF<8HP=AVUI,7,;
M\V+0G1N0PT:]<T3:G4:EUNITY+T<3QKQ$H,S^X!.6LM<@M>#(5CO=+OM7A-E
M;69T[$@(\Q(@%X=*[-BH.H"E6D=GB!='4KR"T+N7@C/)],%5R,87(98VRG"6
M;) !?T#[R#4ZU -6R7D*QH#A864*ZMCT[9YR5]Y^SZD<7S>E5#V811 FO=X
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MLK/>E,S>.A]MZ\C,2+,7 W#CMH<ALPV160^/A39$9HC,$)F195M'9H^/^9L
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M^\*9PC^C:.R^__]02P$"% ,4    "  M2?]0.%3M*;@#  #B#   $0
M        @ $     9VQY8RTR,#(P,#<S,2YX<V102P$"% ,4    "  M2?]0
MFY+2,HT%  #7/   %0              @ 'G P  9VQY8RTR,#(P,#<S,5]L
M86(N>&UL4$L! A0#%     @ +4G_4.P!\#&-!   2RD  !4
M ( !IPD  &=L>6,M,C R,# W,S%?<')E+GAM;%!+ 0(4 Q0    ( "U)_U"_
MSW>M;18  !FL   4              "  6<.  !G;'EC+3(P,C P-S,Q>#AK
M+FAT;5!+ 0(4 Q0    ( "U)_U!_]<HBO"D  +Q] @ 8              "
M 08E  !G;'EC+3(P,C P-S,Q>&5X.3ED,2YH=&U02P4&      4 !0!- 0
&^$X

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
